MENLO PARK, Calif., March 3 /PRNewswire/ -- ForteBio(R), Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Anti-Human IgG Fc Capture (AHC) biosensor for use on the company's Octet(R) instrumentation platform. The new biosensor enables more cost-effective, easy-to-use and rapid kinetic characterization and screening of human IgG antibodies and other Fc-containing proteins - important components in biomolecular therapeutic development - and further broadens the menu of Octet system applications.
"Researchers in bioprocessing and cell line development who study kinetic characterization of human IgG antibodies and other proteins can now benefit from the efficiencies of ForteBio's Octet platform, which enables high-throughput, real-time, label-free detection and screening," said Christopher Silva, ForteBio's vice president of marketing. "The innovative, new AHC biosensor enables off-the-shelf, capture-based kinetics of human IgGs or other Fc-containing proteins without the need to biotinylate. It is also designed for use in buffer or crude supernatants, and can be regenerated and reused for increased cost-efficiency."
The new AHC biosensor leverages the Octet platform's proprietary Bio-Layer Interferometry technology to enable kinetic profiling of human IgGs against analyte in a microplate well format. The biosensor surface can also be used to conduct ligand inhibition assays by expanding the variables that can be measured, such as blocking and unblocking analytes, affinity, and association and dissociation rates. The new AHC biosensor further expands the capabilities of the Octet platform which already supports quantitation of human IgG using Protein A.
ForteBio's Octet biosensors are configured in a standard 96-well format. Its biosensors simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. Octet biosensors are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.
About ForteBio, Inc.
ForteBio is a venture-capital funded life science company providing analytical systems to accelerate biotherapeutic drug development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.
|SOURCE ForteBio, Inc.|
Copyright©2009 PR Newswire.
All rights reserved